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Case Report
Introduction
Surgical resection is the standard treatment for hepatocellular
carcinoma (HCC), which is one of the most common
malignancies in the world. Nonetheless, disease-free survival
for patients with curative resection for HCC remains poor due
to the high incidence of intrahepatic tumour recurrence (50%–
60%).1,2 Repeated hepatectomy has been advocated but the
resection rate is low (10%–35%)3,4 due to limited liver reserve
and multifocality of the tumours. Among the loco-regional
therapies that have been adopted for unresectable HCC,
radiofrequency ablation (RFA) is the most recently developed
treatment modality. It has proven to be safe, with a low
complication rate (0%–12%),5–7 and is widely practised for
unresectable HCC, with a greater than 95% complete tumour
ablation rate.5,8,9 Nevertheless, its serious complications cannot
be overlooked, including injury to major intrahepatic blood
vessels and bile ducts, liver abscess formation, adjacent organ
injury and liver failure. Portal vein thrombosis due to the
blood vessel injury by RFA is rarely reported10 but is potentially
fatal in patients with marginal liver reserve. We present a case
of portal vein thrombosis as a complication after RFA for
recurrent HCC.
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Portal Vein Thrombosis after Radiofrequency Ablation
for Recurrent Hepatocellular Carcinoma
Case report
A 43-year-old hepatitis B carrier had an extended right
hepatectomy for a 7-cm HCC. He developed intrahepatic
tumour recurrence 2 years later, as seen on follow-up computed
tomography (CT), and his serum α-fetoprotein concentration
increased to 399 ng/dL. The diagnosis was confirmed by fine
needle aspiration cytology and there was no evidence of
extrahepatic metastasis. The lesion was unresectable because
it was close to a main branch of the left portal vein, which
was patent, as shown on contrast CT (Figure 1B). There was
minimal arterial enhancement within the lesion (Figure 1A),
to which transarterial chemoembolization (TACE) was
deemed unlikely to be effective due to the scarce blood supply
from the hepatic artery. The patient’s liver function remained
satisfactory, with an indocyanine green retention test of 11%
at 15 minutes.
Open RFA was performed to ablate the tumour. Intra-
operatively, there was a 5 x 6-cm tumour mass (Figure 2A) in
segment III of the liver, and an adjacent portal vein tumour
thrombus (Figure 2B) was identified on intraoperative ultra-
sonography, which otherwise did not reveal additional tumour
within the liver. RFA using the Cool-tip® RF System (Radionics,
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Recurrent hepatocellular carcinoma (HCC) deserves multidisciplinary treatment in addition to surgical resection.
Radiofrequency ablation (RFA) is an evolving, localized, thermal ablative treatment for unresectable hepatocellular
carcinoma (HCC). Though the preliminary results of RFA in clinical studies are encouraging, its serious
complications should not be underestimated. Portal vein thrombosis as a result of direct blood vessel injury by
RFA is rarely reported and is potentially fatal in patients with limited liver reserve due to underlying liver cirrhosis.
We present a case of portal vein thrombosis as a complication of RFA treatment for recurrent HCC and illustrate
its underlying possible mechanism. (Asian J Surg 2003;26(1):50–3)
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Burlington, MA) was performed under ultrasonographic
guidance. No Pringle manoeuvre was applied and complete
ablation of the tumour mass together with the portal vein
tumour thrombus was achieved with a 1-cm margin. There
was no major complication and the patient recovered unevent-
Figure 1. Helical computed tomographic scan of recurrent HCC shows contrast enhancement in the early arterial phase (A) and hypo-
intensity in the portovenous phase (B).
fully. His liver function returned to the preoperative level 5
days after the procedure and he was discharged on postoperative
day 7.
CT was performed 2 weeks after the operation and it
confirmed complete tumour ablation. However, there was
Figure 2. Appearance of tumour (A) on intraoperative ultrasonography. Note portal vein tumour thrombus (B).
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thrombosis of the adjacent portal vein branch as shown in the
portovenous phase of CT (Figure 3A). The patient’s liver
function was deranged, with an increased serum bilirubin
concentration (127 mmol/L) and prolonged prothrombin
time (17.7 sec). Subsequently, he died of diffuse intrahepatic
tumour recurrence 3 months after RFA treatment (Figure 3B).
Discussion
The management of recurrent HCC requires a multidisciplinary
approach. Although repeated hepatectomy is the mainstay
treatment for recurrent HCC, only a minority (30%–35%) of
patients have resectable disease because of limited liver reserve
due to previous surgery, underlying liver cirrhosis and
multifocality of tumour recurrence.3–11 Treatment of
unresectable recurrent HCC relies on various loco-regional
therapies for local tumour control. Traditionally, TACE and
percutaneous ethanol injection (PEI) have been widely practised
with varying degrees of success.12–14 However, TACE may not
be feasible for patients with limited liver reserve. Furthermore,
its efficacy is restricted by several factors including anatomical
changes as a result of previous surgery, collateral blood supply
of tumour other than the hepatic artery, damage to non-
tumorous liver tissue and accumulated drug toxicity. Likewise,
PEI has the disadvantage of a high local recurrence rate (81%
after 3-year follow-up),15 due to failure of ethanol to penetrate
and dissolve the tumour capsule and intra-tumoural septa.
Hence, in recent years, researchers have directed their interest
towards another mode of local ablative therapy using thermal
energy.
RFA is a newly developed thermal ablative therapy for
unresectable HCC. It utilizes high-frequency alternating
current (480 kHz) to generate a lethal temperature for the
tumour and it is unique in producing a predictable and
reproducible thermal ablative lesion. Unlike TACE, RFA does
not rely on the arterial blood supply of tumour and it can
induce in-situ tumour ablation while preserving maximal
normal liver parenchyma. In addition, radiofrequency energy
propagates well beyond the tumour capsule to achieve an
adequate tumour-negative margin, which is impossible with
PEI. Currently, clinical studies involving a total of more than
500 patients treated with RFA have been reported, with a
complication rate of 0%–12% and operative mortality rate of
0%–3%.5–9 Curley et al5 reported the largest series of 110 patients
who underwent RFA treatment for HCC. There was a 100%
complete tumour ablation rate and the ablative site recurrence
rate was 3% after a mean follow-up of 19 months. Because of
the additional haemostatic effect of RFA, its clinical application
can even be extended to HCC with rupture.16
Among the complications of RFA, portal vein thrombosis
as a result of direct blood vessel injury is rarely reported. It is
potentially fatal in patients with marginal liver reserve.
Scudamore et al10 reported a case of portal vein thrombosis
after open RFA for a periportal liver tumour using hepatic
inflow occlusion (Pringle manoeuvre). This complication
reflects the limitation of RFA for liver tumours in close
proximity to the portal vein. Because hepatic blood flow carries
a significant “heat-sink” effect counteracting the RFA
treatment, hepatic inflow occlusion has been shown to enhance
the ablative process in animal studies.17,18 However, this
manoeuvre may be risky when applied to liver tumours close to
the main branch of the portal vein because of the loss of the
protective effect of hepatic blood flow on the vein wall against
RFA. On the other hand, the completeness of tumour ablation
Figure 3. Postoperative computed tomographic scan shows complete ablation of the liver tumour and intrahepatic portal vein thrombosis
(A) and subsequent diffuse intrahepatic tumour recurrence (B).
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along the blood vessel is questionable if the Pringle manoeuvre
is prohibited in this situation.
Our case illustrates a similar clinical condition to that
mentioned. Though we did not apply the Pringle manoeuvre
during RFA treatment, the identified tumour thrombus may
reduce portal venous blood flow to the extent that the affected
portal vein branch became vulnerable to RFA injury. The
resulting detrimental effect of portal vein thrombosis was well
shown in our patient after RFA treatment. Moreover, the
subsequent rapid tumour dissemination in the liver remnant
can be explained by the inadequate tumour control by RFA in
the presence of tumour invasion into the portal vein. In fact,
venous invasion is an independent risk factor for early
intrahepatic recurrence of HCC after curative resection in
multivariate analysis.19
In conclusion, RFA should be avoided in liver tumours
close to the main portal vein branch if there is reduced blood
flow due to any cause, such as a portal vein tumour thrombus
in our patient. Furthermore, in the presence of a portal vein
branch tumour thrombus, RFA may not induce complete
tumour control. Thus, it is not an appropriate treatment from
the oncological point of view.
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